Still no aducanumab filing and an in-house gathering triggered a health disaster, but Biogen's CEO nevertheless took home record pay
2020 got off to one of the most nightmarish starts in the industry at Biogen $BIIB as an annual meeting for its global execs turned into a “superspreader” event that triggered a string of Covid-19 infections in Massachusetts and around the world.
But that didn’t get in the way of some nice bumps in compensation for the executive crew that runs the company — where a contentious argument over its Phase III Alzheimer’s study continues to spark anger and support from every corner.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.